Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.

Nektar Therapeutics produced strong phase 2b data for rezpegaldesleukin in treating eczema this year. That's a vast market where some of the world's best-selling drugs compete, including Dupixent and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...